BSE · 524632
Shukra Pharmaceuticals Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹6 Cr with net profit ₹-2 Cr — a -27.46% net margin, versus 52.03% the period before.
Shareholding
As of 2026-06-30
- Promoter50.96%
- Public48.92%
- FII0%
- DII0.11%
28,384 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 3.83× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #15 of 50 by market cap · medians across 42 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,85,319 Cr | 84.56 | 22.04 | 25.49% | 15.55% |
| Ajanta Pharma Limited | ₹42,933 Cr | 160.96 | 9.52 | 23.33% | 19.37% |
| Gland Pharma Limited | ₹41,520 Cr | 113.07 | 4 | 9.92% | 15.98% |
| Rubicon Research Limited | ₹24,811 Cr | 100.55 | 19.25 | 19.14% | 14.07% |
| Caplin Point Laboratories Ltd. | ₹19,279 Cr | 113.33 | 5.37 | 17.88% | 29.32% |
| Eris Lifesciences Limited | ₹19,056 Cr | 66.76 | 4.88 | 15.87% | 19.89% |
| Shilpa Medicare Ltd. | ₹11,793 Cr | 50.54 | 4.55 | 9.39% | 15.81% |
| Marksans Pharma Limited | ₹11,719 Cr | 28.05 | 3.88 | 13.82% | 14.16% |
| Senores Pharmaceuticals Limited | ₹5,952 Cr | 47.1 | 6.38 | 12.36% | 18.59% |
| Bliss GVS Pharma Ltd. | ₹4,827 Cr | 141.35 | 4.04 | 8.95% | 11.15% |
| Shukra Pharmaceuticals Limited(this company) | ₹1,357 Cr | 62 | 15.11 | 24.55% | 38.88% |
AI analysis
AI-generated · google/gemini-2.5-flashShukra Pharmaceuticals Limited has a market capitalization of Rs 1449 Cr. The company reported a revenue of Rs 36.79 Cr and a profit margin of 38.88%. Its debt-to-equity ratio is 0.06.
Positives
- +The debt-to-equity ratio is low at 0.06.
- +The Return on Capital Employed (ROCE) is 31.4961%.
- +The company has a profit margin of 38.88%.
Negatives
- −The company reported a net loss of Rs -1.72 Cr in the quarter ending March 2026.
- −Revenue significantly decreased from Rs 39.13 Cr in December 2025 to Rs 6.32 Cr in March 2026.
- −No annual revenue growth data is available for analysis.
Financial Performance
In the quarter ending December 2025, Shukra Pharmaceuticals Limited reported revenue of Rs 39.13 Cr, with a net profit of Rs 20.36 Cr. However, in the subsequent quarter ending March 2026, revenue decreased to Rs 6.32 Cr, resulting in a net loss of Rs -1.72 Cr, down from a net profit of Rs 5.39 Cr in March 2025.
Profitability & Returns
The company’s profit margin stands at 38.88%. It has a Return on Equity (ROE) of 24.55% and a Return on Capital Employed (ROCE) of 31.4961%. Earnings per share are Rs 0.5.
Balance Sheet
Shukra Pharmaceuticals Limited maintains a low debt-to-equity ratio of 0.06. The book value per share is Rs 2.05.
Ownership & Pledges
There are no promoter pledges.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Shukra Pharmaceuticals Limitedshare price & fundamentals